The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InIn a move highlighting the accelerating consolidation in life sciences, Merck KGaA has agreed to acquire Bio-Techne Corporation (NASDAQ:TECH) for $73 per share in cash, representing an enterprise value of $11.3 billion (€9.9 billion), according to an official statement. The purchase price reflects a 36% premium to Bio-Techne's one-month volume-weighted average trading price. Bio-Techne shares closed at $31.85 on June 18, the last trading session before the announcement.
The acquisition aims to add Bio-Techne's multi-omics and analytical technologies portfolio, strengthening Merck's presence in high-growth next-generation markets. Merck expects annual cost synergies of approximately €140 million to be fully realized by year three after closing. The deal comes amid a wave of M&A activity in life sciences, as major players pursue strategic acquisitions to broaden their capabilities.
Merck KGaA (MKKGY) shares closed at $31.85 on June 24, while Bio-Techne shares are expected to jump toward the $73 offer price when trading resumes. The transaction is subject to customary regulatory approvals and is expected to close in the second half of 2026. Investors will watch for any regulatory developments or competitor reactions, and further dealmaking in the sector could follow.